MapLight director sells 14,195 MPLT shares for taxes

MapLight Therapeutics director Robert C. Malenka reported open‑market sales of 14,195 shares of Voting Common Stock to cover tax obligations tied to restricted stock unit settlements.

Rhea-AI Filing Summary

MapLight Therapeutics director Robert C. Malenka reported open‑market sales of 14,195 shares of Voting Common Stock to cover tax obligations tied to restricted stock unit settlements. The shares were sold between $18.00 and $19.15 per share across transactions on February 20–24, 2026, leaving him with 325,059 shares held directly. An additional 31,672 shares are held indirectly through the Robert C. Malenka Living Trust, for which he serves as sole trustee with voting and dispositive power, and these retained securities remain subject to a 180‑day IPO lock‑up agreement following the final prospectus dated October 26, 2025.

Insider Trade Summary

Net Seller: 14,195 shares

Net Sell 5 txns

Insider Malenka Robert C.

Role Director

Sold 14,195 shs ($260K)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock	736	$18.15	$13K
Sale	Voting Common Stock	10,788	$18.39	$198K
Sale	Voting Common Stock	476	$19.06	$9K
Sale	Voting Common Stock	2,195	$18.03	$40K
holding	Voting Common Stock	--	--	--

Holdings After Transaction: Voting Common Stock — 325,059 shares (Direct); Voting Common Stock — 31,672 shares (Indirect, See footnote)

Footnotes (6)

1. F1. Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.
2. F2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.01 to $18.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MPLT director Robert C. Malenka report?

Robert C. Malenka reported selling 14,195 shares of MapLight Therapeutics Voting Common Stock in open‑market transactions. The trades occurred between February 20 and 24, 2026 at prices ranging from $18.00 to $19.15 per share, primarily to cover tax obligations from RSU settlements.

At what prices did Robert C. Malenka sell MPLT shares?

He sold MapLight Therapeutics shares at weighted‑average prices within ranges of $18.00–$18.10, $18.00–$18.99, $19.00–$19.15, and $18.01–$18.24. Each reported price reflects a weighted average for multiple trades, with detailed breakdowns available upon request from the company or regulators.

How many MPLT shares does Robert C. Malenka hold after these sales?

After these transactions, Robert C. Malenka directly holds 325,059 shares of MapLight Therapeutics Voting Common Stock. In addition, 31,672 shares are held indirectly by the Robert C. Malenka Living Trust, where he is sole trustee with voting and dispositive power over those trust‑owned shares.

Why did Robert C. Malenka sell MapLight Therapeutics (MPLT) shares?

The filing states these sales were made to cover tax obligations arising from the settlement of restricted stock unit awards. Each restricted stock unit converts into one MapLight Therapeutics common share, and a portion of the resulting shares was sold to satisfy associated tax liabilities.

What does the trust holding mean for MPLT director Robert C. Malenka?

31,672 MapLight Therapeutics shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012. As sole trustee, Malenka has voting and dispositive power over these shares, meaning he controls how they are voted and whether or when they might be transferred or sold.

Are Robert C. Malenka’s remaining MPLT shares subject to a lock-up?

Yes. The filing notes that securities retained by Robert C. Malenka remain subject to a lock‑up agreement with the IPO underwriters. He agreed not to directly or indirectly sell MapLight Therapeutics securities for 180 days following the final prospectus dated October 26, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 06:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malenka Robert C.

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	02/20/2026		S		2,195(1)	D	$18.03(2)	337,059	D
Voting Common Stock	02/23/2026		S		10,788(1)	D	$18.39(3)	326,271	D
Voting Common Stock	02/23/2026		S		476(1)	D	$19.06(4)	325,795	D
Voting Common Stock	02/24/2026		S		736(1)	D	$18.15(5)	325,059	D
Voting Common Stock								31,672	I	See footnote(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.01 to $18.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.